Introduction

▼
Valproic acid (VPA, 2-propylvaleric acid) was fi rst synthesised as an organic solvent by the US chemist Burton in 1881. Its anticonvulsant properties were recognised incidentally in seizure experiments with VPA as a vehicle [ 1 ] . VPA was fi rst released in France in 1967 and has been approved by the US Food and Drug Administration for treatment of epilepsy, bipolar aff ective disorder [ 2 ] and migraine and cluster headaches [ 3 ] . Potentiation of GABA-ergic transmission by inhibition of GABA transaminase [ 4 ] , direct eff ects on potassium channels [ 5 ] , and attenuation of NMDA-receptor-mediated neural excitation [ 6 ] have all been assumed to play a role in the neurochemical activity of VPA, whereas the mood-stabilising function appears to be related to cellular inositol depletion. VPA is considered to be safe when administered according to the well-established therapeutic serum drug level. Nonetheless, Sztajnkrycer described 373 cases of major toxicity and 16 deaths in the USA in the year 2000 after inten-pharmacovigilance study that investigated drug-induced hepatic injury in children between 12 and 17 years of age [ 12 ] . We set out to study the frequency and risk factors of VPA-associated liver failure in a fi rst pharmacovigilance study using data from the German federal authority, irrespective of VPA indication. We sought to determine the roles of the absence or presence of co-medications, gender and age.
Methods
▼
To investigate VPA-associated liver failure, we analysed all reported cases of VPA-associated hepatopathy and liver failure in Germany that had been submitted to the responsible federal authority, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte [BfArM] , UAW Datenbank, Germany), between 1993 and 2009. BfArM is responsible for the surveillance of risks due to medical products in Germany. Among other functions, BfArM records spontaneous reports about serious adverse events from clinicians and gains information through systematic studies of published reports from Germany. Each BfArM report is documented in a separate standard form fi lled out by the reporting clinician. Each case report about VPA-associated liver failure includes age, gender, co-medication, and outcome (fatal vs. non-fatal). Admittance to the data base of cases with VPA-associated hepatotoxicity requires causality classifi ed by BfArM as either "suspected" or "possible". Cases in which a causal relationship between liver failure and VPA use was regarded unlikely were not evaluated because they are not recorded by the BfArM. The cases were analysed irrespective of the indication for administration of VPA or diagnosis and they were studied systematically, regardless of whether they occurred with VPA monotherapy or under a regime of VPA plus comedication. In addition, the correlation between occurrence of VPA-associated hepatotoxicity and gender or age was assessed. In a second step we evaluated the subgroup of fatal VPA-associated liver failures among all cases of VPA-induced hepatotoxicity. We calculated the relative association (percentage) of VPA-associated liver failure for each substance used as a comedication with VPA to establish a rank order of risk for the entire set of cases and for the subgroup of fatal cases. Additionally, case-fatality rates were determined within the medication groups. Finally, we evaluated the number of reported cases of VPA-associated liver failure between 1993 and 2009 and divided the results in 4 time periods (1993-1997, 1998-2001, 2002-2005, and 2006-2009 ) for all cases and for the fatal cases. The frequencies of reported cases across these 4 time intervals were compared with the chi 2 test assuming an equal distribution over time. Furthermore, the association between gender and outcome (non-fatal vs. fatal) was tested for signifi cance using the chi 2 test. Age diff erences between the 2 outcome groups were tested with the the Mann-Whitney U test. 
Results
▼
Multiple mentioning of listed medications allowed; nota bene: * reported percentages in the sub-group with fatal outcome (right column) are based on the total number of cases treated with the respective medication (as given in the left column)
Other co-medications reported in 3 cases or less: β-receptor antagonists, ACE Table 1 ).
In contrast to a preponderance of female patients in the total number of cases, no diff erences in the number of fatal cases were found for men and women (17 vs. 17) . However, the association between gender and outcome (fatal vs. non-fatal) was not statistically signifi cant (chi 2 = 1.36, df = 1, p = 0.244). Regarding age, there was no overall signifi cant diff erence between the groups (fatal and non-fatal liver failure) (z = − 1.61, p = 0.106) (age not reported for 2 of the fatal cases). When inspecting the age distribution of the 2 groups ( • ▶ Fig. 1 ), there seemed to be an increased occurrence of serious hepatic side eff ects in children under 11 (0-10) years while the number of fatalities seemed equally distributed. An exploratory post hoc test of signifi cance revealed that children under 11 have a lower risk of fatality (9 out of 54 = 17 %) as compared to patients with higher age (23 out of 67 = 34 %) (chi 2 = 4.79, df = 1, p = 0.029).
Frequency of reported liver failure cases (1993-2009)
The Discussion ▼ This is the fi rst pharmacovigilance study that evaluated all cases of VPA-associated liver failure with fatal or non-fatal outcome irrespective of the indication of VPA covering all ages (children and adults). Within a total sample of 132 cases of VPA-associated liver failure 34 fatalities occurred, representing the largest published sample of fatal liver failure to date [ 11 ] . As compared with available studies, our pharmacovigilance study based on reported data to the German federal authority between 1993 and 2009 has a comparatively long observation period of 17 years (e. g., 7 years in [ 11 ] ). Considering the total number of cases with serious hepatic adverse eff ects a preponderance of female patients was observed resulting in a female-to-male ratio of 1.41-1. Regarding comedication, one third of the hepatic adverse eff ects were reported to have occurred under VPA monotherapy, while in the majority of the reported cases, VPA was administered with other comedication, most frequently substances with extensive hepatic metabolism such as antiepileptics, benzodiazepines, antipsychotics, diuretics, antidepressants and antibiotics. Approximately one quarter of patients who developed serious hepatic adverse eff ects due to VPA-treatment deceased in the further course (fatal VPA-associated hepatotoxicity). This observation showed no statistically signifi cant diff erence regarding gender and age of aff ected patients. While children under the 11 years of age seem to be particularly at risk for developing any serious hepatic AE related to VPA this age group might feature a lower risk of fatal liver failure. Of the reported fatal cases one third were treated with VPA monotherapy, while two thirds received comedication in addition to VPA. The relative number of fatal cases was similar in patients with monotherapy or with combined medications (about a quarter). To put our results in a larger perspective, Binek and colleagues estimated a risk of 1:5 000 to 1:10 000 of fatal liver failure with VPA in adults [ 13 ] . Dreifuss et al. found this risk to be approximately 1 in 37 000 in adults with VPA monotherapy [ 14 ] ; as for children between 0 and 2 years old receiving valproate as polytherapy, they found a much higher risk of fatalities (1 out of 500 cases). A particularly high risk for fatal hepatotoxicity under VPA was described for patients on additional antiepileptic drugs, with congenital metabolic disorders, with severe epileptic seizures in mental retardation or children, especially those under the age of 2 years (Box Warning [ 15 ] ). Thus, the risk of VPAinduced hepatotoxicity in adults without these additional risk factors was thought to be defi nitely lower. This is in contrast with the study by Koenig et al. who counted 9 fatalities resulting from VPA-induced hepatopathy in Germany from 1994 to 2003 from questionnaires sent to all members of the German section of the League against Epilepsy [ 8 ] . They found that 5 out of 9 reported fatalities occurred in adults and 3 out of 9 patients had VPA monotherapy. Hence, this study was not in line with the generally accepted concept that VPA-induced hepatopathy occurs only in children or adults with risk factors such as polypharmacy [ 11 ] . Bauer et al. even reported a case of fatal fulminant liver failure under VPA monotherapy in a patient with bipolar aff ective disorder without any comorbidity [ 16 ] . The present study supports the view that VPA hepatotoxicity is not restricted to specifi c risk constellations except for age and comedication. We found a slightly higher occurrence of nonfatal hepatic injury in children younger than 11 years while the risk of a fatal outcome was about 2 times lower than in older patients. Otherwise no eff ect of age was observed. The majority of VPA-induced liver failure occurs in patients with VPA plus comedication. This fi nding is consistent with the earlier assumption that polypharmacy is still an important factor in VPAinduced hepatotoxicity. If comedication was present, substances that are extensively metabolised in the liver were found to be common (see • ▶ Table 1 for details), so that in the presence of such substances liver function should be monitored even closer than in VPA monotherapy. The observed increase of registered cases of serious and fatal hepatic side eff ects over time might be explained by either changes in prescription practise or increased reporting to the BfArM pharmacovigilance data base. We are aware of some limitations of our study. As a pharmacovigilance study, it is retrospective and fully depends on the physicians' reporting discipline (leaving room for an unknown number of unreported cases) as well as the quality of the data provided. We cannot explain whether the observed increase in the occurrence of VPA-associated liver failure depends on a better reporting practice or the increased use of VPA in general.
Further, it appears to be possible that comedication was not reported in every case, leading to an overestimation of hepatotoxicity in VPA monotherapy. Our study does not allow for drawing either general causality conclusions or aetiological considerations about VPA-related fatalities and fully relies on the factors reported to the federal authority such as age, gender and comedication. We cannot provide any information regarding the time interval between onset of VPA treatment and the development of liver failure because the BfArM data base does not contain usable information for this important question. In addition, our German data cannot be generalised for other countries.
Thus, similar studies in other countries would be desirable. Across countries the recommended laboratory function tests before and after starting VPA therapy diff er signifi cantly. In Germany, the summary of product characteristics recommends several baseline tests (coagulation parameters including fi brinogen, total protein, whole blood cell count, bilirubin, transaminases, gamma-glutamyl-transferase, lipase and amylase, and serum glucose) and monthly clinical and laboratory controls (transaminases, bilirubin, coagulation parameters and amylase) for half a year; in case of pathologies after 4 weeks, 3 further controls with a maximum delay of 2 weeks each and subsequent monthly controls until 6 months after initiating VPA treatment should be performed [ 17 ] . In children, additional safety measures are recommended (laboratory controls at every second clinical appointment and parent education about signs of liver dysfunction) [ 17 ] . For the United States, the manufacturer recommends that "liver function tests should be performed prior to therapy and at frequent intervals thereafter, especially during the fi rst 6 months" (without providing details about the tests and the intervals) [ 15 ] . Some authors highlighted that severe VPA-associated hepatotoxicity usually manifests within the fi rst 90 days after treatment initiation [ 18 ] and thus, in addition to abovementioned controls recommended by the manufacturers particular attention to clinical and laboratory signs of liver dysfunction should be paid for the fi rst 3 months. Management of VPA-associated hepatoxicity is largely supportive, and the prognosis for patients with acute liver failure due to idiosyncratic drug reactions is poor, with a 60-80 % mortality rate without liver transplantation [ 19 ] . In 2001, Bohan et al. proposed the intravenous use of carnitine because carnitine deficiency, either as a pre-existing condition or induced by VPA therapy, appears to promote VPA-induced liver failure [ 20 ] . Carnitine is well tolerated and has been shown to reduce fatal outcomes if supplementation therapy was initiated early in severe VPA-induced hepatic dysfunction, especially in children [ 9 , 21 , 22 ] . However, further investigation is needed to evaluate its clinical value and the appropriate dosage.
Conclusion
▼
Our study indicates a higher rate of both non-fatal and fatal liver failure associated with VPA plus comedication as compared to VPA monotherapy. However, comedication per se does not increase the risk of fatalities, but is reported in the majority of non-fatal and fatal cases. Particular attention to liver function should be paid when co-medications with extensive hepatic breakdown, e. g.. other antiepileptics (topiramate, carbamazepine, or lamotrigine in particular), benzodiazepines and antipsychotics, are used with VPA. Some comedications such as propofol or heparin appear to have a disproportionally high risk of fatal liver failure when used with VPA. Considering the growing number of reported cases of VPAinduced hepatic failure greater focus on the early detection of VPA-related hepatotoxicity is warranted. From a patient's perspective, detailed knowledge of possible VPA side eff ects is indispensable and patients need suffi cient information about early clinical signs. While patients on VPA should be instructed to immediately seek medical help if gastrointestinal symptoms, general weakness, gait ataxia, or elevated temperature occur, future advances in proteomics, metabonomics and genomics will hopefully pave the way to personalised medications in which the benefi cial eff ect of VPA is maximised and its toxicity minimised.
